Skip to contentC
CNBX Pharmaceuticals Inc.
C
CNBXCNBX Pharmaceuticals Inc. Q3 2020 · 10-Q
Revenue$1.89K$1.89K−12.7% vs Q3 2019 Net Income-$725.68K-$725.68KN/M vs Q3 2019 EPS Diluted-$0.05-$0.05N/M vs Q3 2019 Operating Income-$690,514N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
CNBX Pharmaceuticals Inc. · CIK 1343009 · Engraved from SEC EDGAR
derived
Margins · derivedOperating margin-36612.6%−523.6 pt vs Q3 2019
Net margin-38476.9%−13132.1 pt vs Q3 2019
ended May 31, 2020 · filed Jul 14, 2020 · 44 d after period end